Navigation Links
Pharmaceutical sciences experts present cutting-edge research at international meeting
Date:9/28/2010

Arlington, Va. (Sept. 27, 2010) -- Renowned international experts and scientists will present new research ranging from inhalable vaccines for human papillomavirus and tuberculosis to a non-invasive treatment for lung cancer at the 2010 FIP Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in New Orleans, La., Nov. 14-18.

For the first time, the International Pharmaceutical Federation's (FIP) PSWC and AAPS will join forces and hold the world's largest pharmaceutical sciences meeting to share perspectives, ideas and research to improve global health through advances in pharmaceutical sciences. An estimated 10,000 scientists from more than 60 countries will participate in more than 100 sessions, including 40 symposia and roundtables.

Other meeting highlights include:

  • A keynote address by Dr. Tadataka "Tachi" Yamada, president of the Bill & Melinda Gates Foundation Global Health Program, who will discuss the future of global health;

  • A three-part symposium, "Pharmaceuticals without Borders" that focuses on delivering medicines to underserved populations, regulatory and supply chain challenges, and ensuring integrity and quality of medicines;

  • Symposia on current anti-counterfeiting strategies; and

  • Symposia on bridging the gap between traditional medicine and the Western approach to natural products.


'/>"/>

Contact: Hillarie Turner
hbt@ecius.net
202-296-2002 x113
American Association of Pharmaceutical Scientists
Source:Eurekalert

Page: 1

Related biology news :

1. Chemist to donate potential pharmaceutical royalties to Madagascar
2. Donation for new Center for Pharmaceutical Nanotechnology and Nanotoxicology
3. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
4. Simulating pharmaceutical and personal care product transport
5. Researchers prolong the half-life of biopharmaceutical proteins
6. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
7. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
8. TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
9. NIH awards $8.5 million for research on pharmaceuticals for children
10. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
11. ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
(Date:2/16/2017)... 16, 2017  Rhythm, a biopharmaceutical company ... that result in life-threatening metabolic disorders, today ... mezzanine round of financing with existing investors ... New Enterprise Associates, Pfizer Venture Investments, Third ... investment fund. Rhythm will use the proceeds ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
Breaking Biology Technology: